CEBPA bZIP结构域突变在急性髓系白血病中的预后影响
该研究纳入日本多中心AML基因测序项目登记的1028例AML患者,分析CEBPA突变与预后的关系。发现bZIP结构域内的CEBPA突变与良好预后强相关,而bZIP结构域外的突变无此关联;bZIP内CEBPA突变是OS的最强预测因子(HR 0.3287,P<.001)。
要点
- bZIP结构域内CEBPA突变与高完全缓解率、更好OS和低复发风险强相关。
- bZIP结构域外CEBPA突变未见预后改善。
- bZIP内CEBPA突变在单突变CEBPA亚组中仍显示预后意义。
核心结论
- bZIP结构域内的CEBPA突变是AML预后的强效标志物,有潜力优化治疗分层和靶向治疗开发。
研究设计与样本
- 回顾性分析日本多中心AML基因测序协作项目登记的1028例AML患者。
- 多因素分析纳入744例年龄≤70岁的患者。
主要发现
- bZIP内CEBPA突变与更高完全缓解率(P<.001)、更好OS(P<.001)和更低复发风险(P<.001)相关。
- bZIP外CEBPA突变与良好预后无关。
- 单突变CEBPA亚组中,bZIP内突变仍与更好OS相关(全部患者P=.008;≤70岁且中危核型患者P=.008)。
- 多因素分析显示bZIP内CEBPA突变是OS的最强预测因子(HR 0.3287,P<.001)。
- 双突变CEBPA被验证为与bZIP内CEBPA突变重叠的混杂因素。
关键数值与推荐
- CEBPA突变见于10%至15%的原发性AML病例。
- bZIP内CEBPA突变与OS的HR为0.3287(P<.001)。
- 单突变CEBPA亚组中,bZIP内突变与OS相关P=.008,累积复发率P=.063;≤70岁且中危核型患者OS P=.008,累积复发率P=.026。
临床怎么用
- 对AML患者进行CEBPA突变检测时,应明确突变是否位于bZIP结构域以辅助预后分层。
- bZIP内CEBPA突变可作为治疗分层细化和靶向治疗开发的参考标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations of CCAAT/enhancer-binding protein alpha (CEBPAmu) are found in 10% to 15% of de novo acute myeloid leukemia (AML) cases. Double-mutated CEBPA (CEBPAdm) is associated with a favorable prognosis; however, single-mutated CEBPA (CEBPAsm) does not seem to improve prognosis. We investigated CEBPAmu for prognosis in 1028 patients with AML, registered in the Multi-center Collaborative Program for Gene Sequencing of Japanese AML. It was found that CEBPAmu in the basic leucine zipper domain (bZIP) was strongly associated with a favorable prognosis, but CEBPAmu out of the bZIP domain was not. The presence of CEBPAmu in bZIP was a strong indicator of a higher chance of achieving complete remission (P < .001), better overall survival (OS; P < .001) and a lower risk of relapse (P < .001). The prognostic significance of CEBPAmu in bZIP was also observed in the subgroup with CEBPAsm (all patients: OS, P = .008; the cumulative incidence of relapse, P = .063; patients aged ≤70 years and with intermediate-risk karyotype: OS, P = .008; cumulative incidence of relapse, P = .026). Multivariate analysis of 744 patients aged ≤70 years showed that CEBPAmu in bZIP was the most potent predictor of OS (hazard ratio, 0.3287; P < .001). CEBPAdm was validated as a cofounding factor, which was overlapping with CEBPAmu in bZIP. In summary, these findings indicate that CEBPAmu in bZIP is a potent marker for AML prognosis. It holds potential in the refinement of treatment stratification and the development of targeted therapeutic approaches in CEBPA-mutated AML.
引用
- Wakita S, Sakaguchi M, Oh I, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 2022. PMID: 34448807. doi:10.1182/bloodadvances.2021004292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。